LianBio (LIAN)
| Market Cap | 152.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -113.21M |
| Shares Out | 108.35M |
| EPS (ttm) | -2.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,039 |
| Open | 1.41 |
| Previous Close | 1.41 |
| Day's Range | 1.32 - 1.45 |
| 52-Week Range | 1.07 - 10.36 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 9.92 (+624.1%) |
| Earnings Date | Dec 8, 2022 |
About LIAN
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-li... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for LIAN stock is "Buy." The 12-month stock price forecast is 9.92, which is an increase of 624.09% from the latest price.
News
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...
LianBio to Participate in Upcoming Investor and Industry Events
SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...
LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors
SHANGHAI, China and PRINCETON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
• LIBRA trial designed to support registration in China • Topline results expected in the fourth quarter of 2023
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the...
PARIS & CAMBRIDGE, Mass. & SHANGHAI, China & PRINCETON, N.J.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), a late-stage clinical biotechnology compan...
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
SHANGHAI, China and PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...
LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic C...
• Topline data expected mid-2023
LianBio to Participate in June Investor Events
SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
SHANGHAI, China and PRINCETON, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asia...
LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers
LianBio to Participate in the Bank of America Securities 2022 Healthcare Conference
SHANGHAI, China and PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...
LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Tre...
LianBio Holds Development and Commercialization Rights to TP-03 in Greater China LianBio Holds Development and Commercialization Rights to TP-03 in Greater China
U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York...
LianBio to Continue Development of Camzyos in China and Other Asian Territories LianBio to Continue Development of Camzyos in China and Other Asian Territories
LianBio Announces Formation of Scientific Advisory Board
Scientific Advisory Board strengthens LianBio's mission of bringing novel therapeutics to Greater China and Asia Scientific Advisory Board strengthens LianBio's mission of bringing novel therapeutics to...
LianBio's Partner ReViral Enters into Acquisition Agreement with Pfizer
Acquisition builds on LianBio's existing partnership with Pfizer to bring novel therapeutics to Greater China Acquisition builds on LianBio's existing partnership with Pfizer to bring novel therapeutics...
LianBio Appoints Wei Wei Chen to Board of Directors
SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian mar...
LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing
LianBio Issues Statement Regarding the HFCAA
Company's principal auditor is located in the United States and is currently inspected by the PCAOB Company's principal auditor is located in the United States and is currently inspected by the PCAOB
LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China
SHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian mark...
LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients w...
EXPLORER-CN trial designed to support regulatory filing in Mainland China EXPLORER-CN trial designed to support regulatory filing in Mainland China
LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma i...
SHANGHAI, China and PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...
LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Initiated and completed dosing in pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers
LianBio stock opens below the IPO price, reversing early indications of a rally
LianBio LIAN, -11.38% got off to a rocky start as a public company, as the first trade of the shares of biotechnology company with operations in the U.S. and China was 3.1% below the initial public offe...
LianBio to go public as IPO prices in middle of expected range, as the biotech was valued at about $1.7 billion
LianBio LIAN, -2.22% is set to go public Monday, after the biotechnology company with operations in the U.S. and China said its initial public offering priced at $16 a share, in the middle of the expect...
LianBio Announces Pricing of Initial Public Offering
SHANGHAI, China and PRINCETON, N.J., Oct. 31, 2021 (GLOBE NEWSWIRE) -- LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, tod...